Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3 The Importance of Doing Trials Right
While Doing the Right Trials
David M. Dilts and Steven K. Cheng
See article p. 256

6 Elusive Extraneural Estrogen Receptors in Breast Cancer
Ellis R. Levin
See article p. 118

CCR Drug Updates

9 Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma
Jason J. Luke and F. Stephen Hodi

Molecular Pathways

15 Molecular Pathways: Targeting Proteasomal Protein Degradation in Cancer
Susan M. Molineaux

CCR Focus

22 On Drug Development, Chance, and the Prepared Mind
Susan E. Bates

23 Drug Development: Portals of Discovery
Susan E. Bates, Laleh Amiri-Kordestani, and Giuseppe Giaccone

33 BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance
Alexander Marzuka Alcal, Assunta De Rienzo, Aarti Mathur, Raphael Bueno, and David S. Schrump

40 The Insulin Receptor/Insulin-Like Growth Factor Receptor Family as a Therapeutic Target in Oncology
Michael Pollak

51 Inhibitors Targeting Mitosis: Tales of How Great Drugs against a Promising Target Were Brought Down by a Flawed Rationale
Edina Komlodi-Pasztor, Dan L. Sackett, and Antonio Tito Fojo

HUMAN CANCER BIOLOGY

64 Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?
Len Neckers and Paul Workman

77 Polycomb Repressor Complex-2 Is a Novel Target for Mesothelioma Therapy
Clinton D. Kemp, Mahadev Rao, Sichuan Xi, Suzanne Inchauste, Haresh Mani, Patricia Fetsch, Armando Fille, Mary Zhang, Julie A. Hong, Robert L. Walker, Yueling J. Zhu, R. Taylor Ripley, Aarti Mathur, Fang Liu, Maocheng Yang, Paul A. Meltzer, Victor E. Marquez, Assunta De Rienzo, Raphael Bueno, and David S. Schrump

87 Elusive Extraneural Estrogen Receptors in Breast Cancer
Ellis R. Levin
See article p. 118

91 Eph-B2/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom’s Macroglobulinemia
Feda Azaz, Abdel Kareem Azaz, Patricia Maiso, Teresa Calimeri, Ludmila Flores, Yang Liu, Phong Quang, Aldo M. Roccaro, Antonio Sacco, Hai T. Ngo, Yong Zhang, Britanny L. Morgan, Ruben D. Carrasco, and Irene M. Gobrial

105 Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Dieter Lemke, Philipp-Niclas Pfenning, Felix Sahm, Ann-Catherine Klein, Tore Kempf, Uwe Warnken, Martina Schnolzer, Ruxandra Tudoran, Michael Weller, Michael Platten, and Wolfgang Wick

118 Cytoplasmic Estrogen Receptor in Breast Cancer
Allison W. Welsh, Donald R. Lannin, Gregory S. Young, Mark E. Sherman, Jonine D. Figueroa, N. Lynn Henry, Lisa Ryden, Chungyeul Kim, Richard R. Love, Rachel Schiff, and David L. Rimm
See commentary p. 6

CANCER THERAPY: PRECLINICAL

127 STAT5A-Mediated SOCS2 Expression Regulates Jak2 and STAT3 Activity Following c-Src Inhibition in Head and Neck Squamous Carcinoma
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>263</td>
<td>Skin Tumors Induced by Sorafenib; Paradoxic RAS–RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53, and TGFBR1</td>
<td>Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Holville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussenart, Ludovic Lacroix, Alain Spatz, Alexander M. Eggermont, Sabine Druiillenne, Stephan Vagner, Alain Eychène, Nicolas Dumaz, and Caroline Robert</td>
</tr>
<tr>
<td>273</td>
<td>Concurrent Temozolomide and Dose-Escalated Intensity-Modulated Radiation Therapy in Newly Diagnosed Glioblastoma</td>
<td>Christina I. Tsien, Doris Brown, Daniel Normolle, Matthew Schipper, Morand Pier, Larry Junck, Jason Heth, Diana Gomez-Hassan, Randall K. Ten Haken, Thomas Chenevert, Yue Cao, and Theodore Lawrence</td>
</tr>
<tr>
<td>280</td>
<td>Molecular Determinants of Retinoic Acid Sensitivity in Pancreatic Cancer</td>
<td>Sonal Gupta, Dipankar Pramanik, Radha Mukherjee, Nathaniel R. Campbell, Sathyarayanan Elumalai, Roeland F. de Wilde, Seung-Mo Hong, Michael G. Goggins, Ana De Jesus-Acosta, Daniel Laheru, and Anirban Maitra</td>
</tr>
<tr>
<td>290</td>
<td>TP53 Disruptive Mutations Lead to Head and Neck Cancer Treatment Failure through Inhibition of Radiation-Induced Senescence</td>
<td>Heath D. Skinner, Vlad C. Sandulache, Thomas J. Ow, Raymond E. Meyn, John S. Yordy, Beth M. Beadle, Alison L. Fitzgerald, Uma Giri, K. Xian Ang, and Jeffrey N. Myers</td>
</tr>
<tr>
<td>301</td>
<td>Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial</td>
<td>Annette M. Lim, Danny Rischin, Richard Fisher, Hongbin Cao, Kathleen Kwok, Daniel Truong, Grant A. McArthur, Richard J. Young, Amato Giaccia, Lester Peters, and Quynh-Thu Le</td>
</tr>
<tr>
<td>308</td>
<td>VX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy</td>
<td>Jennifer A. Locke, Gaetano Zafarana, Adrian S. Ishkanian, Michael Milosevic, John Thoms, Cherry L. Have, Chad A. Malloff, Wan L. Lam, Jeremy A. Squire, Melanie Pintilie, Jenna Sykes, Varun Rohan Rammarine, Alice Meng, Omer Ahmed, Igor Jurisica, Theo van der Kwast, and Robert G. Bristow</td>
</tr>
<tr>
<td>317</td>
<td>A CDD Polymorphism as Predictor of Capecitabine-Induced Hand-Foot Syndrome—Letter</td>
<td>Joseph Ciccolini, Alexandre Evrard, and Bruno Lacarelle</td>
</tr>
<tr>
<td>318</td>
<td>Correction: Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance</td>
<td></td>
</tr>
<tr>
<td>319</td>
<td>Correction: ABCB1 (MDR1) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

B7H3 represents a novel driver of gliomagenesis by mediating an immunosuppressive and proinvasive phenotype in glioblastoma. Immunofluorescence demonstrates the perivascularly (alpha-SMA staining; red) enhanced expression of B7H3 (vesicular distribution; green) in human glioblastoma tissue (nuclei staining; blue). For details, see the article by Lemke and colleagues on page 105 of this issue.